Australia Judge Rejects $527 Million Settlement Over Vioxx
This article was originally published in PharmAsia News
An Australian court rejected a class-action settlement that would have had Merck pay 1,700 plaintiffs a maximum of less than $2,000 each for damages caused by its since-withdrawn Vioxx (rofecoxib) arthritis drug.
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.